Your browser doesn't support javascript.
loading
EFhd2/Swiprosin-1 is a common genetic determinator for sensation-seeking/low anxiety and alcohol addiction.
Mielenz, D; Reichel, M; Jia, T; Quinlan, E B; Stöckl, T; Mettang, M; Zilske, D; Kirmizi-Alsan, E; Schönberger, P; Praetner, M; Huber, S E; Amato, D; Schwarz, M; Purohit, P; Brachs, S; Spranger, J; Hess, A; Büttner, C; Ekici, A B; Perez-Branguli, F; Winner, B; Rauschenberger, V; Banaschewski, T; Bokde, A L W; Büchel, C; Conrod, P J; Desrivières, S; Flor, H; Frouin, V; Gallinat, J; Garavan, H; Gowland, P; Heinz, A; Martinot, J-L; Lemaitre, H; Nees, F; Paus, T; Smolka, M N; Schambony, A; Bäuerle, T; Eulenburg, V; Alzheimer, C; Lourdusamy, A; Schumann, G; Müller, C P.
Afiliação
  • Mielenz D; Division of Molecular Immunology, Department of Internal Medicine III, Nikolaus-Fiebiger-Center, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Reichel M; Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Jia T; MRC Social, Genetic and Developmental Psychiatry Research Centre, Institute of Psychiatry, King's College London, London, UK.
  • Quinlan EB; MRC Social, Genetic and Developmental Psychiatry Research Centre, Institute of Psychiatry, King's College London, London, UK.
  • Stöckl T; Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Mettang M; Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Zilske D; Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Kirmizi-Alsan E; Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Schönberger P; Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Praetner M; Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Huber SE; Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Amato D; Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Schwarz M; Institute of Radiology, University Medical Center Erlangen, Erlangen, Germany.
  • Purohit P; Division of Molecular Immunology, Department of Internal Medicine III, Nikolaus-Fiebiger-Center, University Clinic, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Brachs S; Department of Endocrinology, Diabetes and Nutrition, Center for Cardiovascular Research, Charité - University School of Medicine, Berlin, Germany.
  • Spranger J; German Center for Cardiovascular Research, DZHK Partner site Berlin, Berlin, Germany.
  • Hess A; Department of Endocrinology, Diabetes and Nutrition, Center for Cardiovascular Research, Charité - University School of Medicine, Berlin, Germany.
  • Büttner C; German Center for Cardiovascular Research, DZHK Partner site Berlin, Berlin, Germany.
  • Ekici AB; Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
  • Perez-Branguli F; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Winner B; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Rauschenberger V; IZKF Nachwuchsgruppe III, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Banaschewski T; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Bokde ALW; IZKF Nachwuchsgruppe III, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Büchel C; Department of Biology, Developmental Biology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Conrod PJ; Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Desrivières S; Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
  • Flor H; Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Frouin V; Department of Psychiatry, Universite de Montreal, CHU Sainte-Justine Hospital, Montreal, QC, Canada.
  • Gallinat J; Department of Psychological Medicine and Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
  • Garavan H; Medical Research Council - Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
  • Gowland P; Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Heinz A; Neurospin, Commissariat à l'Energie Atomique, CEA-Saclay Center, Paris, France.
  • Martinot JL; Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
  • Lemaitre H; Departments of Psychiatry and Psychology, University of Vermont, Burlington, VT, USA.
  • Nees F; Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK.
  • Paus T; Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité, Universitätsmedizin Berlin, Berlin, Germany.
  • Smolka MN; Institut National de la Santé et de la Recherche Médicale, INSERM Unit 1000 "Neuroimaging & Psychiatry", University Paris Sud, University Paris Descartes - Sorbonne Paris Cité and Maison de Solenn, Paris, France.
  • Schambony A; Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Bäuerle T; Rotman Research Institute, Baycrest and Departments of Psychology and Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Eulenburg V; Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.
  • Lourdusamy A; Department of Biology, Developmental Biology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Schumann G; Institute of Radiology, University Medical Center Erlangen, Erlangen, Germany.
  • Müller CP; Institute of Biochemistry, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
Mol Psychiatry ; 23(5): 1303-1319, 2018 05.
Article em En | MEDLINE | ID: mdl-28397836
ABSTRACT
In many societies, the majority of adults regularly consume alcohol. However, only a small proportion develops alcohol addiction. Individuals at risk often show a high sensation-seeking/low-anxiety behavioural phenotype. Here we asked which role EF hand domain containing 2 (EFhd2; Swiprosin-1) plays in the control of alcohol addiction-associated behaviours. EFhd2 knockout (KO) mice drink more alcohol than controls and spontaneously escalate their consumption. This coincided with a sensation-seeking and low-anxiety phenotype. A reversal of the behavioural phenotype with ß-carboline, an anxiogenic inverse benzodiazepine receptor agonist, normalized alcohol preference in EFhd2 KO mice, demonstrating an EFhd2-driven relationship between personality traits and alcohol preference. These findings were confirmed in a human sample where we observed a positive association of the EFhd2 single-nucleotide polymorphism rs112146896 with lifetime drinking and a negative association with anxiety in healthy adolescents. The lack of EFhd2 reduced extracellular dopamine levels in the brain, but enhanced responses to alcohol. In confirmation, gene expression analysis revealed reduced tyrosine hydroxylase expression and the regulation of genes involved in cortex development, Eomes and Pax6, in EFhd2 KO cortices. These findings were corroborated in Xenopus tadpoles by EFhd2 knockdown. Magnetic resonance imaging (MRI) in mice showed that a lack of EFhd2 reduces cortical volume in adults. Moreover, human MRI confirmed the negative association between lifetime alcohol drinking and superior frontal gyrus volume. We propose that EFhd2 is a conserved resilience factor against alcohol consumption and its escalation, working through Pax6/Eomes. Reduced EFhd2 function induces high-risk personality traits of sensation-seeking/low anxiety associated with enhanced alcohol consumption, which may be related to cortex function.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Ansiedade / Proteínas de Ligação ao Cálcio / Alcoolismo Tipo de estudo: Etiology_studies Limite: Adolescent / Adult / Animals / Female / Humans / Male Idioma: En Revista: Mol Psychiatry Assunto da revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Ansiedade / Proteínas de Ligação ao Cálcio / Alcoolismo Tipo de estudo: Etiology_studies Limite: Adolescent / Adult / Animals / Female / Humans / Male Idioma: En Revista: Mol Psychiatry Assunto da revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Alemanha